Back to top
more

Sorrento Therapeutics (SRNE)

(Delayed Data from OTC)

$0.02 USD

0.02
198,999

0.00 (-16.67%)

Updated Apr 19, 2024 03:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Balance Sheet

Research for SRNE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Sorrento Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents -99,999 50 127 56 36
Receivables NA 24 19 16 15
Notes Receivable NA 0 0 0 0
Inventories NA 10 8 2 3
Other Current Assets NA 12 19 12 14
Total Current Assets NA 96 173 86 68
Net Property & Equipment NA 52 41 32 30
Investments & Advances NA 17 51 256 25
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 217 339 117 102
Deposits & Other Assets NA 4 5 2 287
Total Assets NA 473 695 536 558
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable NA 0 0 0 0
Accounts Payable NA 48 27 46 28
Current Portion Long-Term Debt NA 16 32 23 36
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 241 59 19 35
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 9 9 5 13
Total Current Liabilities NA 328 139 96 115
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 8 121 120 123
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 19 111 92 199
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 55 162 36 35
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 495 617 395 525
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 1,989 1,514 1,172 788
Retained Earnings NA -1,959 -1,387 -958 -660
Other Equity NA -2 0 -24 -46
Treasury Stock NA 49 49 49 49
Total Shareholder's Equity NA -22 78 141 33
Total Liabilities & Shareholder's Equity NA 473 695 536 558
Total Common Equity 0 -22 78 141 33
Shares Outstanding 551.20 471.80 306.30 262.90 167.80
Book Value Per Share 0.00 -0.05 0.26 0.54 0.20

Fiscal Year End for Sorrento Therapeutics, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 -99,999 -99,999 81 50
Receivables NA NA NA 33 27
Notes Receivable NA NA NA NA 0
Inventories NA NA NA 10 11
Other Current Assets NA NA NA 10 13
Total Current Assets NA NA NA 133 101
Net Property & Equipment NA NA NA 53 55
Investments & Advances NA NA NA 12 12
Other Non-Current Assets NA NA NA NA 0
Deferred Charges NA NA NA NA 0
Intangibles NA NA NA 203 204
Deposits & Other Assets NA NA NA 2 3
Total Assets NA NA NA 457 460
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA NA NA NA 0
Accounts Payable NA NA NA 19 15
Current Portion Long-Term Debt NA NA NA 120 50
Current Portion Capital Leases NA NA NA NA 0
Accrued Expenses NA NA NA 99 74
Income Taxes Payable NA NA NA 13 12
Other Current Liabilities NA NA NA 1 1
Total Current Liabilities NA NA NA 265 166
Mortgages NA NA NA NA 0
Deferred Taxes/Income NA NA NA 1 1
Convertible Debt NA NA NA NA 0
Long-Term Debt NA NA NA 22 21
Non-Current Capital Leases NA NA NA NA 0
Other Non-Current Liabilities NA NA 314 315
Minority Interest (Liabilities) NA NA NA NA 0
Total Liabilities NA NA NA 655 587
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA NA NA NA 0
Common Stock (Par) NA NA NA 0 0
Capital Surplus NA NA NA 2,036 2,021
Retained Earnings NA NA NA -2,194 -2,099
Other Equity NA NA NA 9 0
Treasury Stock NA NA NA 49 49
Total Shareholder's Equity NA NA NA -198 -127
Total Liabilities & Shareholder's Equity NA NA NA 457 460
Total Common Equity 0 0 0 99,801 -127
Shares Outstanding 551.20 551.20 551.20 551.20 551.20
Book Value Per Share 0.00 0.00 0.00 181.06 -0.23